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CASE REPORT
An avoidable cause of thymoglobulin 
anaphylaxis
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Abstract 
Background: Thymoglobulin® (anti-thymocyte globulin [rabbit]) is a purified pasteurised, gamma immune globulin 
obtained by immunisation of rabbits with human thymocytes. Anaphylactic allergic reactions to a first injection of 
thymoglobulin are rare.
Case presentation: We report a case of serious anaphylactic reaction occurring after a first intraoperative injection of 
thymoglobulin during renal transplantation in a patient with undiagnosed respiratory allergy to rabbit allergens.
Conclusions: This case report reinforces the importance of identifying rabbit allergy by a simple combination of clini-
cal interview followed by confirmatory skin testing or blood tests of all patients prior to injection of thymoglobulin, 
which is formally contraindicated in patients with a history of hypersensitivity to rabbit proteins.
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Background
Thymoglobulin is an IgG fraction purified from the 
serum of rabbits immunised against human thymocytes. 
The preparation consists of polyclonal antilymphocyte 
IgG directed against T lymphocyte surface antigens, and 
induction of profound lymphocyte depletion is though 
to be the main mechanism of thymoglobulin-mediated 
immunosuppression. Thymoglobulin is now part of 
the standard treatment for intraoperative induction of 
immunosuppression during renal transplantation [1, 2]. 
It can also be used for the prevention and treatment of 
graft-versus-host reaction during haematopoietic stem 
cell transplantation and other organ transplantation, and 
for the treatment of bone marrow aplasia [3–6].
The dosage of thymoglobulin depends on the indica-
tion, the treatment regimen and the possibility of use 
in combination with other immunosuppressive drugs. 
Infusion must be performed under strict surveillance in 
hospital. The main contraindication to administration 
of thymoglobulin is hypersensitivity to rabbit proteins 
[7]. Cases of serious anaphylactic reactions to thymo-
globulin due to rabbit protein allergy are very rare, and 
consequently, specific tests for rabbit allergy are not 
usually performed as part of the pre-transplant assess-
ment. We report a case of serious anaphylactic reaction 
due to rabbit protein allergy following a first injection of 
thymoglobulin.
Case presentation
A 24-year-old Caucasian man was hospitalised in March 
2015 for renal transplantation. He had a history of spina 
bifida, neurogenic bladder with Bricker ileal conduit 
complicated by chronic renal failure requiring haemo-
dialysis since 2011; and atopy, comprising respiratory 
allergy to pollens and house dust mites (asthma and 
rhinitis), contact allergy to latex (angioedema following 
inflation of a toy balloon), and vancomycin drug allergy.
The patient was undergoing renal transplantation 
for the first time. Surgery was performed in a latex-free 
operating room. General anaesthesia was induced by 
intravenous (IV) administration of propofol (150 mg IV 
push), ketamine (35 mg IV push) and sufentanil (20 µg IV 
push). Tracheal intubation was performed without com-
plication and the patient received antibiotic prophylaxis 
by cefoxitin (2 g IV). Forty-five minutes after induction, 
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thymoglobulin immunosuppression (12.5 mg/h of 5 mg/
mL in 50  mL 5% dextrose to be administered over 8  h) 
was initiated. Within 3  min of the start of the thymo-
globulin infusion, the patient experienced hypotension 
of 56/35 mmHg and extreme bradycardia (43 bpm) sec-
ondary to hypoxia, requiring resuscitation with external 
cardiac massage (for less than 1 min) and administration 
of adrenaline (0.1 mg IV push) (Table 1). The thymoglob-
ulin infusion was stopped immediately (at which point 
0.625  mg had been infused). The patient concomitantly 
presented with generalised erythroderma and bronchos-
pasm. He was subsequently managed in the intensive 
care unit and the operation was deferred. A favourable 
course was observed in response to adrenaline 2  mg/h, 
despite another episode of bronchospastic respiratory 
distress several hours later than required terbutaline 
nebulisation. A tryptase assay performed 1 h after onset 
of anaphylactic shock was elevated to 182  µg/L (nor-
mal 10.5  µg/L) confirming the anaphylactic origin of 
the shock. Histamine was also elevated to 234  nmol/L 
(normal < 10 nmol/L).
To explore the origin of the shock, the patient was hos-
pitalised for allergy testing in September 2015. A clini-
cal interview retrospectively revealed a history of atopy 
with asthma and allergic rhinitis and contact hypersen-
sitivity to rabbits triggering asthma and facial oedema. 
Skin tests were performed. Positive (histamine dihydro-
chloride 10  mg/mL equivalent to 1% or 5.43  mmol/L, 
Stallergenes, France) and negative (glycerinate solution) 
controls were included. Skin prick tests (SPTs) were 
carried out and interpreted according to international 
guidelines [8]. The results were read after 10 min and the 
largest diameter was recorded. A skin reaction of ≥3 mm 
was considered positive. The histamine positive control 
response was small (wheal of 2  mm). SPTs and intra-
dermal tests (using a sterile solution of the suspected 
drug serially diluted in phenolated saline) were negative 
for all medications used during induction of anaesthe-
sia [9]: sufentanil, propofol, and ketamine at 10−3, 10−2, 
and 10−1 dilutions; suxamethonium, rocuronium bro-
mide, and cisatracurium besylate at 10−3 and 10−2 dilu-
tions; and atracurium besylate and mivacurium chloride 
at 10−1 dilution. An intradermal test for colloid (Volu-
ven®) was negative at 10−3, 10−2, and 10−1 dilutions. In 
contrast, a SPT for thymoglobulin was positive, with an 
8 mm wheal at a dilution of 10−6. Additional SPTs were 
performed using commercial standardised extracts and 
prickers (Alyostal Prick®, Stallergenes, France). The panel 
included the following allergenic extracts at 100  IR/mL 
or 100  IC/mL: rabbit, hamster, guinea pig, and horse 
epithelia, and latex (a known allergen for this patient). 
The SPTs for rabbit and horse epithelia were positive at 
5 mm; the test for latex was also “positive” but was only 
2  mm. A blood sample was taken for measurement of 
specific IgE (ImmunoCap system, ThermoFisher, Upp-
sala, Sweden). IgE for quaternary ammonium and suxam-
ethonium were <0.10 kU/L and specific IgE for penicillin 
and cefaclor were negative. Specific IgE to rabbit dan-
der and rabbit serum proteins were elevated at 10.2 and 
2.22 kU/L, respectively. IgE specific to rabbit meat was 
0.13 kU/L.
On the basis of clinical and laboratory data, we con-
cluded that the patient had experienced a grade IV ana-
phylactic reaction to thymoglobulin due to rabbit protein 
allergy. All medications containing rabbit proteins will 
be permanently contraindicated for this patient and an 
allergy card was issued. To date, the patient has not been 
transplanted.
Discussion
Anaphylaxis is a hypersensitivity reaction that can rap-
idly become life threatening.
Thymoglobulin administration is generally uneventful 
and anaphylactic reactions are rare. Only 3 cases of aller-
gic anaphylaxis to thymoglobulin have been reported in 
the literature [10–12]; one was a fatal reaction to a thy-
moglobulin carbohydrate excipient rather than anti-thy-
mocyte globulin itself [11]. In the two other cases, renal 
Table 1 Hemodynamic parameters during the operative period
ATG thymoglobulin, bp blood pressure, HR heart rate, MAP mean arterial pressure, PaCO2 partial pressure of CO2, SpO2 haemoglobin oxygen saturation
Before general  
anaesthesia











MAP (mmHg) 139 111 96 43
Diastolic bp (mmHg) 121 89 76 35
HR (bpm) 100 98 72 124
PaCO2 (mmHg) Not intubated 39 32 24
SpO2 (%) 94 98 99 95
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transplant recipients experienced severe IgE reactions to 
thymoglobulin, similar to our case report, but skin tests 
and tryptase dosage were not performed in one case 
[10] and, in the third case, tryptase level was markedly 
increased but no skin test was performed to confirm ana-
phylaxis to thymoglobulin [12]. Reactions to thymoglob-
ulin are usually due to release of cytokines by activated 
monocytes and lymphocytes, known as severe cytokine 
release syndrome, which can be associated with serious 
cardiovascular events. The most common complications 
are haematological (thrombocytopenia, granulocytope-
nia). However, rare cases of serious complications follow-
ing thymoglobulin administration have been reported, 
including serum sickness [13], cardiopulmonary failure 
[14] and acute respiratory distress syndrome [15].
The case of anaphylactic shock reported here was 
observed within minutes of thymoglobulin adminis-
tration, at which time only a very small dose had been 
infused (less than 1  mg). The infusion was immediately 
stopped. This serious reaction required management in 
the intensive care unit and postponement of transplan-
tation. The rapid onset and severity of the anaphylactic 
reaction argue in favour of IgE-mediated anaphylaxis. 
The patient had positive SPTs to both thymoglobulin and 
rabbit dander, strongly implicating a rabbit protein aller-
gic mechanism. The weak positivity of histamine SPT 
was probably related to end stage kidney failure.
Reports of anaphylactic reactions to rabbit proteins are 
rare [16, 17]. One case occured after minor injury with 
a needle that had been used on rabbit tissue [17]. The 
patient had a history of respiratory allergy to rabbits, sug-
gesting a similar mechanism to that reported here. Rab-
bits are becoming increasingly popular as domestic pets 
and lead to sensitization in 1.5% of rabbit ownerships 
[18]. Although rare, one cannot excluse the possibility of 
cross sensitization between domestic pet [19]. The sig-
nificant prevalence of rabbit sensitization and the sever-
ity of allergic reactions related to intravenous infusion 
of rabbit antibodies support the attitude that consists in 
investigating systematically rabbit sensitization before 
the use of preparations containing rabbit antibodies. 
However, screening for rabbit protein allergy is rarely 
performed in the context of complex pre-transplant 
assessment, despite the frequent use of thymoglobulin 
immunosuppression. We think that standardized evalu-
ation including skin prick-tests to rabbit epithelia should 
be systematically performed before rabbit antibodies 
infusion. Millar et al. suggested that skin-testing to thy-
moglobulin should be performed systematically before 
anti-thymocyte globulin injection to aid in determining 
the hypersensitivity status [20]. However, the use of anti-
thymocyte globulin for skin-testing is limited by its avail-
ability and price.
Conclusion
Diagnosis of rabbit protein allergy is the only way to pre-
vent thymoglobulin anaphylaxis such as the case reported 
here. This can be accomplished very easily through a sim-
ple combination of clinical interview followed by con-
firmatory SPT or blood tests.
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